Veraxa Biotech is trading 5.04% higher at $1.25 in pre-market; available evidence does not establish a catalyst. - This compares with the October 1 close of $1.19. - Price history shows a five-session decline before the pre-market rebound. - No clear company-specific announcement for October 2 was found; its latest listed official release is dated September 4. The biotech sector is lower pre-market and does not explain the move.